Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.XDx wins FDA clearance for new gene expression test
According to the company, the AlloMap test is a noninvasive, multi-gene molecular diagnostics blood test used to aid in the identification of heart transplant recipients with stable allograft
According to the company, the AlloMap test is a noninvasive, multi-gene molecular diagnostics blood test used to aid in the identification of heart transplant recipients with stable allograft
The Adagio study showed that Parkinson’s disease (PD) patients who took Azilect (rasagiline) 1mg tablets once-daily upon entry into the trial demonstrated a significant improvement compared to those
The total expansion of Miller Center will provide 34,720 additional square feet to accommodate patients. Riverside Medical Center said that several facilities will be added during the Miller
Chiltern Early Phase provides early phase services for the pharmaceutical industry via its two well-established units in Slough (outside of London) and Dundee, Scotland, according to the company.
Particles Sciences said that this technology has already been used by the company to develop drug-eluting vaginal rings. In their approach, Particle Sciences’s scientists first encapsulate the drug
Novavax said that the vaccine, which does not contain an adjuvant, induced robust neutralizing antibody responses. Novavax’s virus-like particle (VLP) candidate is directed against the H5N1 A/Indonesia/05/2005 avian
The Phase IIa proof-of-concept study is designed to evaluate tumor response in addition to safety and tolerability of Prolarix in 14 patients with non-resectable hepatocellular carcinoma who have
According to the company, the expanded Vyvanse dosing options will allow physicians to individualize treatment for each patient. Vyvanse, which received FDA approval for the treatment of attention
As part of the Healthy Ambition program, Crucell’s operational excellence program, the formulation, filling and packaging of Dukoral in Sweden will stop during 2011 and will move to
This technology, which provides detailed characterization of expressed protein-encoding genes, identifies many non-coding RNAs, and includes sample multiplexing capability, is expected to be available for limited release through